Loading…
ESMO 20th World Congress on Gastrointestinal Cancer has ended

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Wednesday, June 20
 

13:30 PDT

Concurrent Lunch Mini-Symposia
The Revolution in HCC: Translating to the Real World
Presented by Medscape
Room 113-115, Level 1

The Biosimilar Opportunity: Understanding Extrapolation of Indications in GI Cancer
Supported by Amgen Biosimilars
Room 116-117, Level 1

Wednesday June 20, 2018 13:30 - 14:30 PDT
Level 1

14:45 PDT

Session I: Welcome, Selected Abstracts, and Opening Lecture
Session Chair
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Wednesday June 20, 2018 14:45 - 15:50 PDT
Auditorium A, Level 0

14:46 PDT

Welcome and introduction
Faculty
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg


Wednesday June 20, 2018 14:46 - 14:50 PDT
Auditorium A, Level 0

14:50 PDT

Presentation of selected abstracts
Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors
Funda Meric-Bernstam, et al., O-001
 
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety across two global randomized Phase 3 studies (REACH-2 and REACH)
Andrew Zhu, et al., LBA-001
 
The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
Jen Ricke, et al., O-029

Wednesday June 20, 2018 14:50 - 15:20 PDT
Auditorium A, Level 0

15:20 PDT

Opening Lecture: The microbiome in colon cancer
Faculty
avatar for Herbert Tilg

Herbert Tilg

Medical University of Innsbruck


Wednesday June 20, 2018 15:20 - 15:50 PDT
Auditorium A, Level 0

15:50 PDT

Session II: Cancer of the Pancreas and Biliary Tract
Session Chair
avatar for Teresa Macarulla

Teresa Macarulla

Vall D'Hebron University Hospital
avatar for Eileen O'Reilly

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center

Wednesday June 20, 2018 15:50 - 18:30 PDT
Auditorium A, Level 0

15:51 PDT

Genetics in pancreatic cancer: Implications for clinical practice
Faculty
avatar for Zsofia K. Stadler

Zsofia K. Stadler

Memorial Sloan Kettering Cancer Center


Wednesday June 20, 2018 15:51 - 16:10 PDT
Auditorium A, Level 0

16:10 PDT

Are we making progress in surgery of the pancreas?
Faculty
avatar for Baki Topal

Baki Topal

University Hospital Gasthuisberg


Wednesday June 20, 2018 16:10 - 16:30 PDT
Auditorium A, Level 0

16:30 PDT

16:40 PDT

Is adjuvant or neo-adjuvant treatment for resectable pancreatic cancer the way to go?
Neo-adjuvant chemotherapy: Jordan D. Berlin
Surgery plus adjuvant chemotherapy: Pascal Hammel

Faculty
avatar for Jordan D. Berlin

Jordan D. Berlin

Vanderbilt University Medical Center
PH

Pascal Hammel

Hôpital Beaujon


Wednesday June 20, 2018 16:40 - 17:00 PDT
Auditorium A, Level 0

17:00 PDT

Adjuvant treatment of pancreatic cancer
Monotherapy: Jean-Luc Van Laethem
Combination chemotherapy: Thierry Conroy

Faculty
avatar for Thierry Conroy

Thierry Conroy

Institut de Cancérologie de Lorraine – Alexis Vautrin
avatar for Jean-Luc VanLaethem

Jean-Luc VanLaethem

Erasme University Hospital


Wednesday June 20, 2018 17:00 - 17:20 PDT
Auditorium A, Level 0

17:20 PDT

Presentation of selected abstracts
Geographic variation in systemic treatment of metastatic pancreatic adenocarcinoma (mPAC) patients in real world across Europe
Julien Taieb, et al., O-002

Gemcitabine with nab-paclitaxel in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC): a quality of life randomized cross-over study (QOLINPAC)
Gabriela Chiritescu, et al., O-003

Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (Mpdac) in the global NAPOLI-1 phase III trial
Teresa Macarulla Mercadé. et al., O-004

Wednesday June 20, 2018 17:20 - 17:50 PDT
Auditorium A, Level 0

17:50 PDT

18:10 PDT

New agents/strategies on the horizon in bile duct cancer
Faculty
avatar for Michel Ducreux

Michel Ducreux

Institut Gustave Roussy


Wednesday June 20, 2018 18:10 - 18:30 PDT
Auditorium A, Level 0

19:00 PDT

Concurrent Evening Nonprofit Symposia
ESDO European Research Workshop 2018 Hereditary GI Cancers: State of the Art in Screening and Surveillance
Presented by European Society of Digestive Oncology
Room 116, Level 1

15th ESO Colorectal Cancer Observatory: Innovations and Care in the Next 12 Months
Presented by European School of Oncology
Room 117, Level 1

Wednesday June 20, 2018 19:00 - 20:30 PDT
Level 1
 
Thursday, June 21
 

08:00 PDT

Session III: Meet the Expert Concurrent Presentations
Parallel with Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer; also Parallel with Session V: Interpreting Clinical Trials Results

Thursday June 21, 2018 08:00 - 08:50 PDT
Level 1

08:00 PDT

Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer
Parallel with Session III: Meet the Expert Concurrent Presentations; also Parallel with Session V: Interpreting Clinical Trials Results

Session Chair
avatar for Andrés Cervantes

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia
avatar for Erika Martinelli

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli

Thursday June 21, 2018 08:00 - 09:30 PDT
Auditorium B, Level 0

08:00 PDT

Session V: Interpreting Clinical Trials Results
Parallel with Session III: Meet the Expert Concurrent Presentations; also Parallel with Session IV: Presentation of Selected Abstracts on Non-Colorectal Cancer

Session Chair
avatar for Axel Grothey

Axel Grothey

Sarah Cannon Research Institute
avatar for Rachel Riechelmann

Rachel Riechelmann

AC Camargo Cancer Center

Thursday June 21, 2018 08:00 - 09:30 PDT
Auditorium A, Level 0

08:01 PDT

08:01 PDT

Advances in surgery of rectal cancer: Workshop
Faculty
avatar for Andre D'Hoore

Andre D'Hoore

University Hospital Gasthuisberg
avatar for Rodrigo Perez

Rodrigo Perez

Instituto do Câncer do Estado de São Paulo, University of São Paulo


Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 122-123, Level 1

08:01 PDT

Carcinoma of unknown origin
Faculty
avatar for George Pentheroudakis

George Pentheroudakis

University of Ioannina


Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 131-132, Level 1

08:01 PDT

New endoscopic screening tools: How do they help us?
Faculty
avatar for Nadir Arber

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University
avatar for Jaroslaw Regula

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology


Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 120-121, Level 1

08:01 PDT

Teaching on new evolutions in radiation oncology
Session Chair
avatar for Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg

Faculty
avatar for Vincenzo Valentini

Vincenzo Valentini

Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli


Thursday June 21, 2018 08:01 - 08:50 PDT
Rooms 133-134, Level 1

08:01 PDT

Presentations of selected abstracts
A Multicentre, Prospective Clinical Evaluation Study For Analyzing RAS Mutational Status Utilizing Plasma Circulating Tumor DNA In Patients With Metastatic Colorectal Cancer
Yoshinori Kagawa, et al., O-005

Ultra-selection of metastatic colorectal cancer patients using Next Generation Sequencing platform to improve clinical efficacy of anti-EGFR therapy
Joana Vidal, et al., O-006

Liquid biopsy allows predicting benefit from rechallenge with cetuximab(cet)+irinotecan(iri) in RAS/BRAF wild-type mCRC patients(pts) with resistance to 1st-line cet+iri: final results and translational analyses of the CRICKET study by GONO
Daniele Rossini, et al., O-007

The prognostic role of microsatellite status, tumor mutational burden and protein expression in CRC
Justina Lam, et al., O-008
 
A Phase II multi institutional study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers (BTC)
Richard Kim, et al., O-009

Cisplatin/5-Fluorouracil +/- Panitumumab for Patients with Non-resectable, Advanced or Metastatic Esophageal Squamous Cell Cancer: A Randomized phase III AIO/EORTC Trial with an Extensive Biomarker Program
Markus Moehler, et al., O-010

Thursday June 21, 2018 08:01 - 09:10 PDT
Auditorium B, Level 0

08:20 PDT

08:40 PDT

What to use and to improve the evaluation of responses

The role of PET/CT in functional imaging: Christoph Deroose, Leuven

The role of MRI in functional imaging: Raquel Perez-Lopez, Barcelona


Faculty
avatar for Christoph Deroose

Christoph Deroose

University Hospital Gasthuisberg
avatar for Raquel Perez-Lopez

Raquel Perez-Lopez

Vall d'Hebron Institute of Oncology


Thursday June 21, 2018 08:40 - 09:20 PDT
Auditorium A, Level 0

09:10 PDT

Highlights of posters at ESMO GI on non-CRC
Faculty
avatar for Erika Martinelli

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli


Thursday June 21, 2018 09:10 - 09:30 PDT
Auditorium B, Level 0

09:20 PDT

09:30 PDT

Session VI: Esophageal and Gastric Cancers
Session Chair
avatar for Michel Ducreux

Michel Ducreux

Institut Gustave Roussy
avatar for Kei Muro

Kei Muro

Aichi Cancer Center Hospital

Thursday June 21, 2018 09:30 - 11:00 PDT
Auditorium A, Level 0

09:31 PDT

Management of squamous cell cancer for the esophagus
Definitive CRT: Florian Lordick
Neoadjuvant therapy followed by surgery: David H. Ilson

Faculty
avatar for David H. Ilson

David H. Ilson

Memorial Sloan Kettering Cancer Center
avatar for Florian Lordick

Florian Lordick

University Cancer Center Leipzig


Thursday June 21, 2018 09:31 - 09:55 PDT
Auditorium A, Level 0

09:55 PDT

Locally advanced GE junction cancer
CRT: David H. Ilson
Peri-operative CT: David Cunningham

Faculty
avatar for David Cunningham

David Cunningham

Royal Marsden NHS Foundation Trust
avatar for David H. Ilson

David H. Ilson

Memorial Sloan Kettering Cancer Center


Thursday June 21, 2018 09:55 - 10:20 PDT
Auditorium A, Level 0

10:20 PDT

Is FLOT the only standard in the perioperative setting for gastric cancer?
Faculty
avatar for Andrés Cervantes

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia


Thursday June 21, 2018 10:20 - 10:30 PDT
Auditorium A, Level 0

10:30 PDT

11:00 PDT

Break and poster viewing
Posters to be presented: Non-CRC abstracts

Thursday June 21, 2018 11:00 - 11:30 PDT
Exhibition Hall

11:00 PDT

Poster discussion guided tours

Group 1 Discussant: Brigette Ma, Hong Kong
Group 2 Discussant: Thomas Seufferlein, Ulm
Group 3 Discussant: Eileen O'Reilly, New York


Faculty
avatar for Brigetta Ma

Brigetta Ma

Chinese University of Hong Kong
avatar for Eileen O'Reilly

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center
avatar for Thomas Seufferlein

Thomas Seufferlein

Ulm University


Thursday June 21, 2018 11:00 - 11:30 PDT
Exhibition Hall

11:30 PDT

Session VII: Gastric Cancer
Session Chair
avatar for Fatima Carneiro

Fatima Carneiro

Ipatimup and Medical Faculty
avatar for David Cunningham

David Cunningham

Royal Marsden NHS Foundation Trust

Thursday June 21, 2018 11:30 - 13:10 PDT
Auditorium A, Level 0

11:31 PDT

12:00 PDT

Presentation of selected abstracts
Overall survival results from a Phase III trial of trifluridine/tipiracil vs. placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS)
Josep Tabernero, et al., LBA-002
 
KEYNOTE-061: phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer
Kohei Shitara, et al., LBA-005

Thursday June 21, 2018 12:00 - 12:30 PDT
Auditorium A, Level 0

12:30 PDT

12:50 PDT

Metastatic gastric cancer: New targeted agents in metastatic gastric cancer
Faculty
avatar for David H. Ilson

David H. Ilson

Memorial Sloan Kettering Cancer Center


Thursday June 21, 2018 12:50 - 13:10 PDT
Auditorium A, Level 0

13:10 PDT

Lunch
Thursday June 21, 2018 13:10 - 15:10 PDT
Level 0

13:25 PDT

Concurrent Lunch Symposia
Optimizing Holistic Patient Outcomes in Advanced Gastric/GEJ Cancer Across the Sequence of Therapy
Supported by Lilly
Rooms 111-112, Level 1

What Can We Expect from Today's and Tomorrow's Treatments in mCRC and mGC?
Supported by Servier
Rooms 113-115, Level 1

Optimizing the Continuum of Care for Patients with Pancreatic Cancer: A Case Study-Based Debate
Supported by Celgene
Rooms 116-117, Level 1

Thursday June 21, 2018 13:25 - 14:55 PDT
Level 1

15:10 PDT

Session VIII: Diseases and Cancers of the Liver
Session Chair
avatar for Thomas Seufferlein

Thomas Seufferlein

Ulm University
avatar for Chris Verslype

Chris Verslype

University Hospital Gasthuisberg

Thursday June 21, 2018 15:10 - 16:40 PDT
Auditorium A, Level 0

15:11 PDT

15:40 PDT

Tumor board on HCC
Session Chair
avatar for Chris Verslype

Chris Verslype

University Hospital Gasthuisberg

Faculty
avatar for Ghassan Abou-Alfa

Ghassan Abou-Alfa

Memorial Sloan Kettering Cancer Center
RA

René Adam

Paul Brousse Hospital
avatar for Jordan D. Berlin

Jordan D. Berlin

Vanderbilt University Medical Center
avatar for Christoph Deroose

Christoph Deroose

University Hospital Gasthuisberg
avatar for Thomas Seufferlein

Thomas Seufferlein

Ulm University


Thursday June 21, 2018 15:40 - 16:10 PDT
Auditorium A, Level 0

16:10 PDT

Presentation of selected abstract
Assessment of Tumor Response, AFP Response, and Time to Progression in the Phase 3 CELESTIAL Trial of Cabozantinib Versus Placebo in Advanced Hepatocellular Carcinoma (HCC)
Philippe Merle, et al., O-011

Thursday June 21, 2018 16:10 - 16:20 PDT
Auditorium A, Level 0

16:20 PDT

How to integrate new agents in HCC
Faculty
avatar for Ghassan Abou-Alfa

Ghassan Abou-Alfa

Memorial Sloan Kettering Cancer Center


Thursday June 21, 2018 16:20 - 16:40 PDT
Auditorium A, Level 0

16:40 PDT

Break and poster viewing
Posters to be presented: Clinical/basic non-CRC abstracts

Thursday June 21, 2018 16:40 - 17:10 PDT
Exhibition Hall

17:10 PDT

Session IX: Expert Highlights: What is New in This disease?
During this session, experts from a range of specialties will highlight the last 12 months of evidence-based strategies and emerging data on neuroendocrine tumors (NETs), gastrointestinal stromal tumors (GIST), anal and bile duct cancers as well as trends for 2019.

Session Chair
avatar for Nadir Arber

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center

Thursday June 21, 2018 17:10 - 19:00 PDT
Auditorium A, Level 0

17:11 PDT

What is new in NET in the last 12 months?
Faculty
avatar for Marianne Pavel

Marianne Pavel

University Hospital Erlangen


Thursday June 21, 2018 17:11 - 17:30 PDT
Auditorium A, Level 0

17:30 PDT

What is new in GIST in the last 12 months?
Faculty
avatar for John Zalcberg

John Zalcberg

Monash University


Thursday June 21, 2018 17:30 - 17:50 PDT
Auditorium A, Level 0

17:50 PDT

What is new in anal cancer in the last 12 months?
Faculty
avatar for Michel Ducreux

Michel Ducreux

Institut Gustave Roussy


Thursday June 21, 2018 17:50 - 18:10 PDT
Auditorium A, Level 0

18:10 PDT

What is new in bile duct cancer in the last 12 months?
Faculty
JW

Juan W. Valle

University of Manchester


Thursday June 21, 2018 18:10 - 18:30 PDT
Auditorium A, Level 0

18:30 PDT

Keynote Lecture: Protein Biosynthesis in Healthy Cells and in Cancer Cells
Faculty
avatar for Ada E. Yonath

Ada E. Yonath

Nobel Prize Laureate, Weizmann Institute of Science


Thursday June 21, 2018 18:30 - 19:00 PDT
Auditorium A, Level 0

19:00 PDT

 
Friday, June 22
 

08:00 PDT

Session XIII: Prevention and Screening of Colon Cancer
Parallel with Session X: Case Discussion on Liver Metastases; Parallel with Session XI: Presentation of Selected Abstracts: Colorectal Cancer; also Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists

Session Chair
avatar for Nadir Arber

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University
avatar for Jaroslaw Regula

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology

Friday June 22, 2018 08:00 - 09:10 PDT
Auditorium B, Level 0

08:00 PDT

Session X: Case Discussion on Liver Metastases
Parallel with Session XI: Presentation of Selected Abstracts: Colorectal Cancer; Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists; also Parallel with Session XIII: Prevention and Screening of Colon Cancer

Friday June 22, 2018 08:00 - 09:20 PDT
Rooms 120-121, Level 1

08:00 PDT

Session XII: ESMO Session: Focus on Young Medical Oncologists
Parallel with Session X: Case Discussion on Liver Metastases; Parallel with Session XI: Presentation of Selected Abstracts: Colorectal Cancer; also Parallel with Session XIII: From Epidemiology to Prevention of GI Cancer

Session Chair
avatar for Guillem Argilés

Guillem Argilés

Vall D'Hebron University Hospital
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Friday June 22, 2018 08:00 - 09:20 PDT
Rooms 133-134, Level 1

08:00 PDT

Session XI: Presentation of Selected Abstracts: Colorectal Cancer
Parallel with Session X: Case Discussion on Liver Metastases; Parallel with Session XII: ESMO Session: Focus on Young Medical Oncologists; also Parallel with Session XIII: Prevention and Screening of Colon Cancer

Session Chair
JB

Johanna Bendell

Sarah Cannon Research Institute
avatar for Roberto Labianca

Roberto Labianca

Ospedale Giovanni XXIII

Friday June 22, 2018 08:00 - 09:30 PDT
Auditorium A, Level 0

08:01 PDT

Presentation of selected abstract
Plasma miRNAs signature validation for early detection of colorectal cancer
Marta Herreros-Villanueva, et al., O-044

Friday June 22, 2018 08:01 - 08:10 PDT
Auditorium B, Level 0

08:01 PDT

08:01 PDT

Presentation of selected abstracts
Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer (mCRC) in routine clinical practice: Final analysis from prospective, observational CORRELATE study
Michel Ducreux, et al., O-012

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study
Alfredo Falcone, et al., O-013

Regorafenib dose optimization study (reDOS): Randomized phase II trial to evaluate escalating dosing strategy and pre-emptive topical steroids for regorafenib in refractory metastatic colorectal cancer (mCRC)- An ACCRU network study
Tanios Bekaii-Saab, et al., O-014
 
Discussant: Roberto Labianca

Faculty
avatar for Roberto Labianca

Roberto Labianca

Ospedale Giovanni XXIII


Friday June 22, 2018 08:01 - 08:40 PDT
Auditorium A, Level 0

08:01 PDT

Locoregional treatment for liver metastases: How to choose within the toolbox and when to go for locoregional treatments
Session Chair
avatar for Bernard Nordlinger

Bernard Nordlinger

Hospital Ambroise Paré

Faculty
avatar for Peter Gibbs

Peter Gibbs

Walter and Eliza Hall Institute of Medical Research
avatar for Thomas Gruenberger

Thomas Gruenberger

Kaiser-Franz-Josef Hospital
avatar for Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg
avatar for Rachel Riechelmann

Rachel Riechelmann

AC Camargo Cancer Center
avatar for Julien Taieb

Julien Taieb

Hôpital Européen Georges-Pompidou


Friday June 22, 2018 08:01 - 09:20 PDT
Rooms 120-121, Level 1

08:10 PDT

08:20 PDT

Drugging TGF-beta pathway as a way to foster immune responses in mCRC
Faculty
avatar for Daniele Tauriello

Daniele Tauriello

Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology


Friday June 22, 2018 08:20 - 08:40 PDT
Rooms 133-134, Level 1

08:30 PDT

Screening for colon cancer: What has been achieved in 2018 and new prospects
Faculty
avatar for Jaroslaw Regula

Jaroslaw Regula

Maria Skłodowska Curie Memorial Cancer Centre and Institute of Oncology


Friday June 22, 2018 08:30 - 08:50 PDT
Auditorium B, Level 0

08:40 PDT

The importance of having a mentor in the European oncology environment
Faculty
avatar for Andrés Cervantes

Andrés Cervantes

INCLIVA Biomedical Research Institute, University of Valencia


Friday June 22, 2018 08:40 - 09:00 PDT
Rooms 133-134, Level 1

08:40 PDT

Presentation of selected abstracts
A two-arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results
Gabriela Chiritescu, et al., O-015

First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC): The VALENTINO study
Filippo Pietrantonio, et al., O-016

FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in mCRC: final results of the phase II randomized MOMA trial by GONO
Federica Marmorino, et al., O-017
 
Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab plus cobimetinib and atezolizumab monotherapy vs. regorafenib in chemotherapy-refractory
Johanna Bendell, et al., LBA-004

Randomized trial of irinotecan and cetuximab (IC) versus irinotecan, cetuximab and ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following oxaliplatin and bevacizumb based therapy: Result of E7208
Howard Hochster, et al., O-030


Friday June 22, 2018 08:40 - 09:30 PDT
Auditorium A, Level 0

08:50 PDT

Will chemoprevention become a reality?
Faculty
avatar for Nadir Arber

Nadir Arber

Tel Aviv Medical Center, Tel Aviv University


Friday June 22, 2018 08:50 - 09:10 PDT
Auditorium B, Level 0

09:00 PDT

How to find a good mentor in Europe
Faculty
avatar for Erika Martinelli

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli


Friday June 22, 2018 09:00 - 09:20 PDT
Rooms 133-134, Level 1

09:30 PDT

Session XIV: Highlights
Session Chair
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Friday June 22, 2018 09:30 - 10:35 PDT
Auditorium A, Level 0

09:31 PDT

Keynote Lecture: Understanding relevant immune mechanisms in GI oncology
Faculty
avatar for Pierre Coulie

Pierre Coulie

Université catholique de Louvain, Institut de Duve


Friday June 22, 2018 09:31 - 10:00 PDT
Auditorium A, Level 0

10:00 PDT

Keynote Lecture: Coping with escalating healthcare costs in 2018 and beyond
Faculty
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital


Friday June 22, 2018 10:00 - 10:30 PDT
Auditorium A, Level 0

10:30 PDT

10:35 PDT

Break and poster viewing
Abstracts to be presented: Clinical/basic CRC abstracts

Friday June 22, 2018 10:35 - 11:05 PDT
Exhibition Hall

10:35 PDT

Poster discussion guided tours
Group 1 Discussant: Bernard Nordlinger
Group 2 Discussant: Thomas Seufferlein
Group 3 Discussant: Gerald Prager

Faculty
avatar for Bernard Nordlinger

Bernard Nordlinger

Hospital Ambroise Paré
GP

Gerald Prager

Medical Unviersity of Vienna
avatar for Thomas Seufferlein

Thomas Seufferlein

Ulm University


Friday June 22, 2018 10:35 - 11:05 PDT
Exhibition Hall

11:05 PDT

Session XV: Multimodality Therapy for Rectal Cancer
Session Chair
avatar for Regina G.H. Beets-Tan

Regina G.H. Beets-Tan

The Netherlands Cancer Institute
avatar for Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg

Friday June 22, 2018 11:05 - 12:45 PDT
Auditorium A, Level 0

11:06 PDT

11:35 PDT

Debate: This house believes multiparametric MRI is the holy grail for organ preservation in rectal cancer
For the motion: Regina Beets-Tan
Against the motion: Karin Haustermans

Faculty
avatar for Regina G.H. Beets-Tan

Regina G.H. Beets-Tan

The Netherlands Cancer Institute
avatar for Karin Haustermans

Karin Haustermans

University Hospital Gasthuisberg


Friday June 22, 2018 11:35 - 11:55 PDT
Auditorium A, Level 0

11:55 PDT

Rectal cancer after neoadjuvant therapy with complete clinical response
Surgery: Eric Rullier
Watchful waiting: Rodrigo Perez

Faculty
avatar for Rodrigo Perez

Rodrigo Perez

Instituto do Câncer do Estado de São Paulo, University of São Paulo
ER

Eric Rullier

Haut-Lévêque Hospital


Friday June 22, 2018 11:55 - 12:15 PDT
Auditorium A, Level 0

12:15 PDT

Evolution and innovations in rectal cancer surgery
Faculty
avatar for Andre D'Hoore

Andre D'Hoore

University Hospital Gasthuisberg


Friday June 22, 2018 12:15 - 12:35 PDT
Auditorium A, Level 0

12:35 PDT

Presentation of selected abstract
PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabin +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up
Hans-Joachim Schmoll, et al., O-019

Friday June 22, 2018 12:35 - 12:45 PDT
Auditorium A, Level 0

12:45 PDT

Lunch
Friday June 22, 2018 12:45 - 14:45 PDT
Level 0

13:00 PDT

Concurrent Lunch Symposia
New Treatment Paradigms in GI Cancers: Targeted and Immunotherapy Combinations in mCRC and Advanced HCC
Supported by Roche
Rooms 111-112, Level 1

Bridging Data to Clinical Practice for Patients with Metastatic Colorectal Cancer: An Interactive Peer-to-Peer Discussion
Supported by Sanofi Genzyme
Rooms 113-115, Level 1

Advancing Clinical Practice and Patient Care in RAS Wild-Type mCRC
Supported by Amgen
Rooms 116-117, Level 1

Friday June 22, 2018 13:00 - 14:30 PDT
Level 1

14:45 PDT

Session XVI: Molecular Biology in CRC
Session Chair
avatar for Fortunato Ciardiello

Fortunato Ciardiello

ESMO Representative, Second University of Naples
avatar for Brigetta Ma

Brigetta Ma

Chinese University of Hong Kong

Friday June 22, 2018 14:45 - 16:45 PDT
Auditorium A, Level 0

14:46 PDT

How to approach the patient with a BRAF mutant tumor
Faculty
avatar for Chloe Atreya

Chloe Atreya

UCSF Helen Diller Family Comprehensive Cancer Center


Friday June 22, 2018 14:46 - 15:05 PDT
Auditorium A, Level 0

15:05 PDT

Current status and perspectives on liquid biopsies in GI cancer
Faculty
avatar for Fortunato Ciardiello

Fortunato Ciardiello

ESMO Representative, Second University of Naples


Friday June 22, 2018 15:05 - 15:25 PDT
Auditorium A, Level 0

15:25 PDT

Is circulating DNA relevant in stage II colon cancer?
Faculty
avatar for Peter Gibbs

Peter Gibbs

Walter and Eliza Hall Institute of Medical Research


Friday June 22, 2018 15:25 - 15:45 PDT
Auditorium A, Level 0

15:45 PDT

16:05 PDT

Is broad NGS testing useful in patients with metastatic colorectal cancer?
Pro: Rodrigo Dienstmann
Con: Howard Hochster

Faculty
avatar for Rodrigo Dienstmann

Rodrigo Dienstmann

Vall d'Hebron Institute of Oncology
avatar for Howard Hochster

Howard Hochster

Rutgers Cancer Institute of New Jersey


Friday June 22, 2018 16:05 - 16:35 PDT
Auditorium A, Level 0

16:35 PDT

Presentation of selected abstract
Activity of larotrectinib in patients with TRK fusion GI malignancies
Michael Nathenson, et al., O-020

Friday June 22, 2018 16:35 - 16:45 PDT
Auditorium A, Level 0

16:45 PDT

Break and poster viewing
Posters to be presented: Clinical/basic CRC abstracts

Friday June 22, 2018 16:45 - 17:15 PDT
Exhibition Hall

17:15 PDT

Session XVII: Immune Mechanisms and Immune Therapy in GI Cancer
This session will highlight the mechanisms of action, pathways, and rationale for using immunotherapy to treat GI malignancies, assess guideline recommendations for biomarker testing to guide treatment selection across tumor types, evaluate the clinical profiles of current and emerging therapies designed to inhibit the deleterious effects of these diseases, evaluate safety and efficacy data reported to date, and assess potential clinical applications.

Session Chair
avatar for Ali Shamseddine

Ali Shamseddine

American University of Beirut Medical Center
avatar for Alberto Sobrero

Alberto Sobrero

ESMO Representative, IRCCS Ospedale San Martino IST

Friday June 22, 2018 17:15 - 18:20 PDT
Auditorium A, Level 0

17:16 PDT

Presentation of selected abstract
Safety and Antitumor Activity of Pembrolizumab in Patients with Advanced Microsatellite Instability–High (MSI-H) Colorectal Cancer: KEYNOTE-164
Dung Le, et al., O-021

Friday June 22, 2018 17:16 - 17:25 PDT
Auditorium A, Level 0

17:25 PDT

Highlights of Posters at ESMO GI on colorectal cancer
Faculty
avatar for Takayuki Yoshino

Takayuki Yoshino

National Cancer Center Hospital East


Friday June 22, 2018 17:25 - 17:40 PDT
Auditorium A, Level 0

17:40 PDT

How to increase immunogenicity in MSS CRC
Faculty
avatar for Guillem Argilés

Guillem Argilés

Vall D'Hebron University Hospital


Friday June 22, 2018 17:40 - 18:00 PDT
Auditorium A, Level 0

18:00 PDT

Are we making progress with Immuno-Oncologic in pancreatic cancer?
Faculty
avatar for Eileen O'Reilly

Eileen O'Reilly

Memorial Sloan Kettering Cancer Center


Friday June 22, 2018 18:00 - 18:20 PDT
Auditorium A, Level 0

18:20 PDT

18:21 PDT

What do the new evolutions in GI cancer mean for my practice?
South America: Jorge Gallardo
Middle East: Ali Shamsheddine
Asia: Brigette Ma

Faculty
avatar for Jorge Gallardo

Jorge Gallardo

Chilean Foundation for Oncology Development
avatar for Brigetta Ma

Brigetta Ma

Chinese University of Hong Kong
avatar for Ali Shamseddine

Ali Shamseddine

American University of Beirut Medical Center


Friday June 22, 2018 18:21 - 19:10 PDT
Auditorium A, Level 0
 
Saturday, June 23
 

08:30 PDT

Session XIX: Colorectal Cancer: How to Deal with New Treatments
Session Chair
avatar for Alberto Sobrero

Alberto Sobrero

ESMO Representative, IRCCS Ospedale San Martino IST
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital

Saturday June 23, 2018 08:30 - 09:30 PDT
Auditorium A, Level 0

08:31 PDT

How can we deal with the explosion of new treatments
FDA: Steven Lemery
EMA: Jorge Camarero
ESMO: Jean-Yves Douillard

Faculty
avatar for Jorge Camarero

Jorge Camarero

CHMP, European Medicines Agency/Spanish Medicines Agency
JD

Jean-Yves Douillard

European Society for Medical Oncology
SL

Steven Lemery

United States Food & Drug Administration


Saturday June 23, 2018 08:31 - 09:30 PDT
Auditorium A, Level 0

09:30 PDT

Session XX: Colorectal Cancer
Session Chair
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Saturday June 23, 2018 09:30 - 10:40 PDT
Auditorium A, Level 0

09:31 PDT

Presentation of selected abstracts
Phase II study evaluating trifluridine/tipiracil+bevacizumab and capecitabine+bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are non-eligible for intensive therapy (TASCO1): results of the primary analysis
Eric Van Cutsem, et al., O-022

FOLFOX/Bevacizumab +/- Irinotecan in advanced colorectal cancer (CHARTA): long term outcome
Hans-Joachim Schmoll, et al., O-023

mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild- type metastatic colorectal cancer m(CRC): a randomized phase II VOLFI trial of the AIO (AIO- KRK0109)
Michael Geissler, et al., O-024
 
Selecting the optimal first-line treatment in advanced colorectal cancer: 
Discussion of abstracts O-022 to O-024
David Cunningham

Faculty
avatar for David Cunningham

David Cunningham

Royal Marsden NHS Foundation Trust


Saturday June 23, 2018 09:31 - 10:10 PDT
Auditorium A, Level 0

10:10 PDT

10:25 PDT

10:40 PDT

Break
Saturday June 23, 2018 10:40 - 11:10 PDT
Level 0

11:10 PDT

Session XX: Colorectal Cancer (Continued)
Session Chair
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Saturday June 23, 2018 11:10 - 13:10 PDT
Auditorium A, Level 0

11:11 PDT

How to improve on the outcome in RAS mutant tumors
Faculty
avatar for Heinz-Josef Lenz

Heinz-Josef Lenz

USC Norris Comprehensive Cancer Center


Saturday June 23, 2018 11:11 - 11:30 PDT
Auditorium A, Level 0

11:30 PDT

Presentation of selected abstracts
Association between tumor mutation burden (TMB) and MLH1, PMS2, MSH2, and MSH6 alterations in 395 microsatellite instability-high (MSI-High) gastrointestinal (GI) tumors
Mohamed Salem, et al., O-025

Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy
Julian Hamfjord, et al., O-026

BEACON CRC Study Safety Lead-in: Assessment of the BRAF Inhibitor Encorafenib + MEK Inhibitor Binimetinib + Anti–Epidermal Growth Factor Receptor Antibody Cetuximab for BRAFV600E Metastatic Colorectal Cancer
Eric Van Cutsem, et al., O-027

Discussant: Ramon Salazar

Faculty
avatar for Ramon Salazar

Ramon Salazar

Catalan Institute Of Oncology


Saturday June 23, 2018 11:30 - 12:10 PDT
Auditorium A, Level 0

12:10 PDT

12:30 PDT

Presentation of selected abstract
Long-term effect of peripheral sensory neuropathy (PSN) of 3 or 6 months oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: ACHIEVE as part of the IDEA collaboration
Shintaro Takeuchi, et al., O-028

Saturday June 23, 2018 12:30 - 12:40 PDT
Auditorium A, Level 0

12:40 PDT

13:10 PDT

Lunch
Saturday June 23, 2018 13:10 - 15:10 PDT
Level 0

13:25 PDT

Concurrent Lunch Symposia
Contemporary Management of Metastatic Pancreatic Cancer: Exploring the Nuances of Patient Care Across the Disease Continuum
Presented by prIME Oncology
Rooms 113-115, Level 1

Optimizing Sequencing of Regorafenib in the Treatment of CRC, HCC, GIST, and Other Solid Tumors
Supported by Bayer
Rooms 116-117, Level 1

Saturday June 23, 2018 13:25 - 14:55 PDT
Level 1

15:10 PDT

Session XXI: From 1999 to 2018 and Beyond
Session Chair
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center
avatar for Bernard Nordlinger

Bernard Nordlinger

Hospital Ambroise Paré

Saturday June 23, 2018 15:10 - 16:40 PDT
Auditorium A, Level 0

15:11 PDT

Celebration Lecture: The history of GI cancer: What has been achieved over the last 20 years?
As the standard of care and novel strategies for the management of GI malignancies continue to evolve, this session will highlight the most impactful research advances and clinical discoveries that have been instrumental in reducing mortality and morbidity associated with these diseases over the past 20 years.

Faculty
avatar for Aimery DeGramont

Aimery DeGramont

Institut Hospitalier Franco-Britannique


Saturday June 23, 2018 15:11 - 15:40 PDT
Auditorium A, Level 0

15:40 PDT

Multidisciplinary tumor board on resectable and borderline/potentially resectable liver metastases
Session Chair
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Faculty
avatar for Axel Grothey

Axel Grothey

Sarah Cannon Research Institute
avatar for Erika Martinelli

Erika Martinelli

Università degli Studi della Campania L. Vanvitelli
avatar for Bernard Nordlinger

Bernard Nordlinger

Hospital Ambroise Paré


Saturday June 23, 2018 15:40 - 16:10 PDT
Auditorium A, Level 0

16:10 PDT

Molecular and hereditary tumor board
Session Chair
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg

Faculty
avatar for Heinz-Josef Lenz

Heinz-Josef Lenz

USC Norris Comprehensive Cancer Center
avatar for Brigetta Ma

Brigetta Ma

Chinese University of Hong Kong
avatar for Ramon Salazar

Ramon Salazar

Catalan Institute Of Oncology
avatar for Zsofia K. Stadler

Zsofia K. Stadler

Memorial Sloan Kettering Cancer Center


Saturday June 23, 2018 16:10 - 16:40 PDT
Auditorium A, Level 0

16:40 PDT

16:41 PDT

Presentation of outcome of expert consensus discussion
Faculty
avatar for Mario Dicato

Mario Dicato

Chair, Luxembourg Medical Center
avatar for Josep Tabernero

Josep Tabernero

Vice Chair, ESMO Representative, Vall d’Hebron University Hospital
avatar for Eric VanCutsem

Eric VanCutsem

Chair, University Hospital Gasthuisberg


Saturday June 23, 2018 16:41 - 17:10 PDT
Auditorium A, Level 0
 
Filter sessions
Apply filters to sessions.